Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.

Authors

Institutions

Publication Details

Journal
iMeta
Published
2024-12-31
DOI
https://doi.org/10.1002/imt2.265
Citations
13
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Tingyu Fang, Hao Guo, Beatriz Garcia Mendes, Xingyao Chen et al.
13 citations
iMeta
Gut microbiota and health
3.04
article

Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Tingyu Fang, Hao Guo, Beatriz Garcia Mendes, Xingyao Chen, Huikuan Chu, Sonja Lang, Zhongshang Yuan, Juntao Shen, Constanze Hoebinger, Shu Zhu, Yue Pan, Lei Dai, Zhuo Chen, Yi Duan, Lianmin Chen, Yongjian Zhou, Yuru Zong, Yongpeng Shi, Ling Yang, Su-Ling Zeng, Shi Yin, Tim Hendrikx, Peng Chen, Hua Wang, Hanqing Chen, Jie Zheng, Hailong Cao, Hao Qin, Min Lian, X. Ma, Bernd Schnabl, Youpeng Deng
article en
13 citations

Abstract

Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.

iMetaVol. 4(1)
University of Science and Technology of China (CN), Union Hospital (HK), Nanchang University (CN), Shandong University (CN), Sun Yat-sen University (CN), University of Cologne (DE), Shanghai Jiao Tong University (CN), Capital Medical University (CN), Xiamen University (CN), Anhui Medical University (CN), Chinese Academy of Sciences (CN), Renji Hospital (CN), Ruijin Hospital (CN), Tianjin Medical University General Hospital (CN), University of Bristol (GB), University of California San Diego (US), Universidade Federal de Santa Catarina (BR), Sun Yat-sen Memorial Hospital (CN), Zhujiang Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), National Center for Nanoscience and Technology (CN), Shenzhen Institutes of Advanced Technology (CN), Jiangsu Province Hospital (CN), University Hospital Cologne (DE), Huazhong University of Science and Technology (CN), Tianjin Medical University (CN), Southern Medical University (CN), Medical University of Vienna (AT), Nanjing Medical University (CN), South China University of Technology (CN)
National Natural Science Foundation of China, Chinese Academy of Sciences, China Postdoctoral Science Foundation, Natural Science Foundation of Guangdong Province, China Academy of Chinese Medical Sciences, Fundamental Research Funds for the Central Universities, National Institute of Diabetes and Digestive and Kidney Diseases
Zero hunger
Openalex Percentile: Top 8%
Gut microbiota and health
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.